98612-60-3

Basic information

• Product Name: (R)-5-BROMOMETHYL-2-PYRROLIDINONE
• Synonyms: (5R)-5-(broMoMethyl)pyrrolidin-2-one;(R)-5-(BroMoMethyl)pyrrolidin-2-one;(R)-5-BROMOMETHYL-2-PYRROLIDINONE;2-Pyrrolidinone, 5-(bromomethyl)-, (5R)-;[R,(+)]-5α-(Bromomethyl)pyrrolidine-2-one;[R,(+)]-5α-Bromomethyl-2-pyrrolidone;B50370
• CAS NO: 98612-60-3
• Molecular Formula: C₅H₈BrNO
• Molecular Weight: 178.03
• Product Categories: pharmacetical
• Mol File: 98612-60-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 76-80°C
• Boiling Point: 336.1 °C at 760 mmHg
• Flash Point: 157.1 °C
• Appearance: /
• Density: 1.541 g/cm³
• Vapor Pressure: 0.000115mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: 2-8°C
• PKA: 15.39±0.40(Predicted)
• CAS DataBase Reference: (R)-5-BROMOMETHYL-2-PYRROLIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-5-BROMOMETHYL-2-PYRROLIDINONE(98612-60-3)
• EPA Substance Registry System: (R)-5-BROMOMETHYL-2-PYRROLIDINONE(98612-60-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 98612-60-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C5H8BrNO/c6-3-4-1-2-5(8)7-4/h4H,1-3H2,(H,7,8)/t4-/m1/s1

Upstream product

• 6893-26-1 D-Glutamic acid 
• 128899-31-0 <(2R)-5-oxopyrrolidin-2-yl>methyl 4-methylbenzenesulfonate 
• 64700-65-8 methyl (2R)-pyroglutamate 
• 66673-40-3 (R)-5-hydroxymethylpyrrolidin-2-one 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 

Downstream Products

• 63328-11-0 (5R)-5-benzylpyrrolidin-2-one 
• 119603-16-6 majusculamide D 
• 98612-63-6 (-)-AKS 19 

Relevant articles and documents

Highly Convergent Total Synthesis and Assignment of Absolute Configuration of Majusculamide D, a Potent and Selective Cytotoxic Metabolite from Moorea sp.

The total synthesis of majusculamide D (MJS-D) is described, a lipopentapeptide originally isolated from Lyngbya majuscula and reisolated from a Moorea sp. MJS-D possesses selective and potent cancer cell toxicity. A scalable and convergent strategy with a minimal number of purifications produced significant quantities of MJM-D for in vivo evaluations. The absolute configuration of the 1,3-dimethyl-octanamide motif was determined by synthesis of this fragment via ZACA chemistry.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Developing microcolin A analogs as biological probes

Three microcolin A and B analogs have been synthesized. Their biological activity profiles were evaluated against several cell lines, revealing the existence of a structural determinant whose role in mediating the antiproliferative effect of the microcoli